Detailed Overview: MHRA New Drug Risks (2024)
The Medicines and Healthcare Products Regulatory Agency (MHRA) prioritises drug safety by issuing updates on emerging risks. Here’s a breakdown of some key new risks from 2024:
1️⃣ Fluoroquinolone Antibiotics: Restricted Use
Fluoroquinolones (e.g., ciprofloxacin, levofloxacin), widely prescribed for bacterial infections, are now recommended only when no other antibiotics are appropriate. The MHRA reviewed reports of serious adverse reactions, including:
- Tendonitis and tendon rupture
- Long-term nerve damage (peripheral neuropathy)
- Aortic aneurysm and aortic dissection
These severe side effects are particularly concerning for the elderly, patients with renal impairment, and those using corticosteroids(
...
Читати далі »